Reposted by Fengtastic
How is EQ-5D data analysed in clinical trials?
With EQ-5D increasingly used in economic evaluations, findings in this systematic review highlight an urgent need for better guidance & standardisation in statistical approaches.
A must-read for trialists, health economists, and HTA professionals 👇
With EQ-5D increasingly used in economic evaluations, findings in this systematic review highlight an urgent need for better guidance & standardisation in statistical approaches.
A must-read for trialists, health economists, and HTA professionals 👇
The EQ-5D has been commonly collected in many randomized clinical trials. However, it is not clear how it has been analyzed and reported. This systematic review focuses on how EQ-5D data were analyzed to estimate treatment effect in these trials. www.valueinhealthjournal.com/article/S109...
Statistical Methods for Analyzing EQ-5D in Randomized Clinical Trials: A Systematic Literature Review
We conducted a systematic literature review to summarize the application of statistical
methods for analyzing treatment effect on EQ-5D in randomized clinical trials (RCTs).
www.valueinhealthjournal.com
April 17, 2025 at 11:45 AM
How is EQ-5D data analysed in clinical trials?
With EQ-5D increasingly used in economic evaluations, findings in this systematic review highlight an urgent need for better guidance & standardisation in statistical approaches.
A must-read for trialists, health economists, and HTA professionals 👇
With EQ-5D increasingly used in economic evaluations, findings in this systematic review highlight an urgent need for better guidance & standardisation in statistical approaches.
A must-read for trialists, health economists, and HTA professionals 👇
Reposted by Fengtastic
CEVR is thrilled to announce the winners of our 7th Annual Cost-Effectiveness Paper of the Year Award.
Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646)
#CEA #HEOR
Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646)
#CEA #HEOR
Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States - PharmacoEconomics
Objective Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of acquiring human immunodeficiency virus (HI...
tinyurl.com
April 9, 2025 at 8:38 PM
CEVR is thrilled to announce the winners of our 7th Annual Cost-Effectiveness Paper of the Year Award.
Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646)
#CEA #HEOR
Best CEA — Anita Brogan et al. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States (tinyurl.com/mw5ff646)
#CEA #HEOR
The EQ-5D has been commonly collected in many randomized clinical trials. However, it is not clear how it has been analyzed and reported. This systematic review focuses on how EQ-5D data were analyzed to estimate treatment effect in these trials. www.valueinhealthjournal.com/article/S109...
Statistical Methods for Analyzing EQ-5D in Randomized Clinical Trials: A Systematic Literature Review
We conducted a systematic literature review to summarize the application of statistical
methods for analyzing treatment effect on EQ-5D in randomized clinical trials (RCTs).
www.valueinhealthjournal.com
April 9, 2025 at 3:50 PM
The EQ-5D has been commonly collected in many randomized clinical trials. However, it is not clear how it has been analyzed and reported. This systematic review focuses on how EQ-5D data were analyzed to estimate treatment effect in these trials. www.valueinhealthjournal.com/article/S109...
Exemptions from the Medicare drug price negotiation program could have unintended consequences on pharmaceutical innovation, particularly for small biotech companies and patients with rare diseases. www.healthaffairs.org/do/10.1377/f...
Medicare’s Drug Price Negotiation And Innovation: What’s Off The Table Matters Too | Health Affairs Forefront
Certain exemptions from the Medicare drug price negotiation program could have unintended consequences on pharmaceutical innovation, particularly for small biotech companies and patients with rare diseases.
www.healthaffairs.org
February 21, 2025 at 2:44 PM
Exemptions from the Medicare drug price negotiation program could have unintended consequences on pharmaceutical innovation, particularly for small biotech companies and patients with rare diseases. www.healthaffairs.org/do/10.1377/f...
“The ‘new’ R&D ecosystem has given us some very effective drugs, but it has also become a machine converting money from patients, employers, and taxpayers into private wealth.”
A brilliant, must-read piece if you are interested in drug pricing!
www.healthaffairs.org/content/fore...
A brilliant, must-read piece if you are interested in drug pricing!
www.healthaffairs.org/content/fore...
The Real Reasons Drug Prices Are So High | Health Affairs Forefront
Key policies introduced over the past 45 years have brought new research organizations and investors into the pharmaceutical R&D process, increasing industry’s market power relative to that of private...
www.healthaffairs.org
December 13, 2024 at 1:34 AM
“The ‘new’ R&D ecosystem has given us some very effective drugs, but it has also become a machine converting money from patients, employers, and taxpayers into private wealth.”
A brilliant, must-read piece if you are interested in drug pricing!
www.healthaffairs.org/content/fore...
A brilliant, must-read piece if you are interested in drug pricing!
www.healthaffairs.org/content/fore...